Skip to main
  1. Stocks
  2. Relay Therapeutics, Inc.
  3. Forecast
RLAY

RLAY Stock Forecast & Price Target

RLAY Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 55%
Buy 45%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Relay Therapeutics is viewed favorably because its Dynamo platform is designed to unlock previously intractable targets, while the clinical pipeline led by zovegalisib is generating encouraging data across vascular anomalies and breast cancer. The company reported 2Q26 net loss of $0.41 per share, with R&D of $76.5M and SG&A of $14.7M, yet still ended 2Q26 with $910.9M in cash, implying an operational runway into 2029 and reducing near-term financing risk. The combination of strong efficacy signals, a 24.51% short interest, and multiple expected updates by end-2026 and in 1H27 creates a compelling setup for a meaningful re-rating if upcoming results confirm prior progress.

Bears say

Relay Therapeutics is exposed to substantial clinical risk because drug development is inherently uncertain, and its assets may fail to show sufficient efficacy or safety in current or future trials. Its prospects also depend on securing FDA and foreign regulatory approval, where any delay or failure could undermine commercialization, while the oncology field is intensely competitive against larger, better-resourced biotechnology and pharmaceutical peers. Financially, the company is likely to need additional equity financing through a secondary offering to fund development of its drug candidates, creating dilution risk for existing shareholders.

RLAY has been analyzed by 11 analysts, with a consensus rating of Buy. 55% of analysts recommend a Strong Buy, 45% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Relay Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.

RLAY Analyst Forecast & Price Prediction

Get the latest RLAY stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in RLAY

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Relay Therapeutics, Inc. (RLAY) Forecast

Analysts have given RLAY a Buy based on their latest research and market trends.

According to 11 analysts, RLAY has a Buy consensus rating as of Nov 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $27.09, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $27.09, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Relay Therapeutics, Inc. (RLAY)


RLAY Analyst Forecast & Price Prediction

Get the latest RLAY stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in RLAY

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover RLAY stock data and trends